CEO Paul Brennan said; “We welcome the opportunity to work with Al Mofadaly to expand our reach throughout the middle-east. Our NovoSorb BTM will offer patients in the region a significant improvement in their clinical outcomes and enable us to serve our global key opinion leaders”.
Ho ho ho
Ann: NovoSorb BTM approved for sale in Saudi Arabia, page-2
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.61 |
Change
0.160(6.53%) |
Mkt cap ! $1.802B | |||
| Open | High | Low | Value | Volume |
| $2.50 | $2.61 | $2.48 | $4.801M | 1.866M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2558 | $2.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.61 | 64745 | 5 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| PNV (ASX) Chart |